Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Larazotide acetate reduces symptoms in celiac patients undergoing a gluten challenge

A study published ahead of print in the Alimentary Pharmacology & Therapeutics examines larazotide acetate in patients with celiac disease undergoing a gluten challenge.

News image

Celiac disease, an autoimmune disorder triggered by gluten ingestion, is managed by a gluten-free diet, which is difficult for many patients.

Larazotide acetate is a first-in-class oral peptide that prevents tight junction opening, and may reduce gluten uptake and associated sequelae.
 
Dr Kelly and colleagues from Massachussetts, USA evaluated the efficacy and tolerability of larazotide acetate during gluten challenge.
 
The research team performed an exploratory, double-blind, randomized, placebo-controlled study including 184 patients who maintained a gluten-free diet before and during the study.

After a gluten-free diet run-in, patients were randomized to larazotide acetate or placebo, and received 2.7 grams of gluten daily for 6 weeks.

Larazotide acetate 1-mg limited gluten-induced symptoms
Alimentary Pharmacology & Therapeutics

The researchers' outcomes included an experimental biomarker of intestinal permeability, the lactulose-to-mannitol ratio and clinical symptoms assessed by Gastrointestinal Symptom Rating Scale, and anti-transglutaminase antibody levels.
 
The research team observed no significant differences in lactulose-to-mannitol ratios between larazotide acetate and placebo groups.

Larazotide acetate 1-mg limited gluten-induced symptoms measured by Gastrointestinal Symptom Rating Scale.

Mean ratio of anti-tissue transglutaminase IgA levels over baseline was 19 in the placebo group compared with 6, 4 and 8 in the larazotide acetate 1-, 4-, and 8-mg groups, respectively.

The team found that the adverse event rates were similar between larazotide acetate and placebo groups.
 
Dr Kelly and colleagues commented, "Larazotide acetate reduced gluten-induced immune reactivity and symptoms in patients with celiac disease undergoing gluten challenge and was generally well tolerated."

"However, no significant difference in lactulose-to-mannitol ratios between larazotide acetate and placebo was observed."

"Results and design of this exploratory study can inform the design of future studies of pharmacological interventions in patients with celiac disease."

Aliment Pharmacol Ther 2012: DOI: 10.1111/apt.12147
28 November 2012

Go to top of page Email this page Email this page to a colleague

 03 August 2015

Advanced search
 03 August 2015 
Vaccinations and IBD
 03 August 2015 
Lack of response to therapy in severe ulcerative colitis
 03 August 2015 
Nutritional vs biological therapy in Crohn's
 31 July 2015 
Prognostic index for hep C-related cirrhosis
 31 July 2015 
Risk of hepatocellular carcinoma in chronic HCV with diabetes
 31 July 2015 
Reducing surgical site infection after stoma reversal
 30 July 2015 
Post-colonoscopy colorectal cancer rates
 30 July 2015 
Venous thromboembolism in colorectal surgery
 30 July 2015 
Saccharomyces boulardii for antibiotic-associated diarrhea
 29 July 2015 
Sitafloxacin-based triple therapy for H.pylori
 28 July 2015 
Lifestyle changes after colorectal cancer screening
 27 July 2015 
Fecal microbiota transplantation for severe C. difficile infection
 24 July 2015 
Causes of death in celiac disease
 23 July 2015 
Reduction in H. pylori prevalence
 22 July 2015 
Detection of esophageal eosinophilia and eosinophilic esophagitis
 21 July 2015 

Clinical outcomes for Barrett's esophagus neoplasia

 20 July 2015 
Certolizumab pegol for Crohn's disease
 17 July 2015 
Genetic variation and gastric cancer
 17 July 2015 
Colitis associated with anti-CTLA-4 therapy
 17 July 2015 

Sexual dysfunction after rectal cancer treatment

 16 July 2015 
Lynch syndrome screening by microsatellite instability
 16 July 2015 
Hormones and endometrial cancer in Lynch syndrome
 16 July 2015 
Relapse of IBD after discontinuation of anti-TNF therapy
 15 July 2015 
Risk prediction index for advanced colorectal cancer
 15 July 2015 
Aspergillus niger-derived enzymes
 15 July 2015 
Prophylactic omeprazole improves GI symptoms
 14 July 2015 
Interferon- and ribavirin-free treatment regimen for HCV
 14 July 2015 
Combination therapies for chronic HCV
 14 July 2015 
Cancer surveillance in ulcerative colitis
 13 July 2015 
Colon polyps in chronic inflammatory conditions of the colon
 13 July 2015 
Drugs and occult vs overt upper GI bleeds
 13 July 2015 
Anxiety and depression in functional GI disorders
 10 July 2015 
Daclatasvir in the treatment of chronic HCV
 10 July 2015 
Surveillance intervals to reduce colorectal cancer
 10 July 2015 
Stress and GI symptoms in IBD
 09 July 2015 
Opioid-induced esophageal dysfunction
 09 July 2015 
Marker of response to medical therapy in Crohn's
 09 July 2015 
Predictive factors for metastasis in colorectal cancer
 08 July 2015 
Chronic unexplained nausea and vomiting
 08 July 2015 

Nucleoside analogue therapy in HBeAg-negative chronic hepatitis B?

 08 July 2015 

Medical education in endoscopy training

 07 July 2015 
Anastomotic leak after elective surgery for colonic cancer
 07 July 2015 
Fecal transplantation for ulcerative colitis
 07 July 2015 
Obesity and risk of hepatocellular carcinoma
 06 July 2015 
Fecal microbiota transplantation
 06 July 2015 
Liver Failure–Sequential Organ Failure Scoring System
 06 July 2015 
Future colorectal surgery for metachronous cancers
 03 July 2015 
Tumors with mismatch-repair deficiency
 03 July 2015 
Aptitude of trainees in endoscopic ultrasonography
 03 July 2015 
Extracolonic pathologies in colorectal cancer
 02 July 2015 
Ulcerative colitis prognosis after thiopurines withdrawal
 02 July 2015 
Anastomotic leak and cancer cancer
 02 July 2015 
Health care use by IBD children
 01 July 2015 
Missed gastric cancers
 01 July 2015 
Oral mechanical bowel preparation
 01 July 2015 
Probiotics in IBD
 30 June 2015 
Split-dose preparations vs day-before bowel cleansing regimens
 30 June 2015 
Glucocorticoids and peptic ulcer bleeding
 30 June 2015 
NSAIDs and hearburn symptoms
 29 June 2015 
Prevention of pancreatitis after ERCP

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us